恶性肿瘤淋巴管生的研究进展-国际临床研究杂志-CSCIED科技核心评价数据库-手机版

恶性肿瘤淋巴管生的研究进展

Research progress on lymphangiogenesis of malignant tumors

ES评分 0 浏览量：50 下载量：0

DOI	10.12208/j.ijcr.20250230
刊名	国际临床研究杂志 International Journal of Clinical Research
年，卷(期)	2025, 9(5)
作者	李姣¹,郑盛²*,杨涓²,
作者单位	1 大理大学临床医学院云南大理,2 大理大学第二附属医院云南昆明
摘要	恶性肿瘤淋巴管生成是指在肿瘤微环境中，淋巴管内皮细胞（LECs）通过增殖、迁移和管腔形成等过程，生成新的淋巴管。这一过程在肿瘤转移中起着至关重要的作用，是肿瘤淋巴转移的重要机制。因此，深入理解淋巴管生成的机制对于寻找新的治疗靶点和早期诊断标志物至关重要。本文综述的目的是探讨相关淋巴管生成的分子机制，并分析肿瘤微环境与淋巴管内皮细胞之间的相互作用，旨在为相关淋巴管生成的研究和临床诊疗提供新的视角。
Abstract	Malignant tumor lymphangiogenesis refers to the generation of new lymphatic vessels by lymphatic endothelial cells (LECs) in the tumor microenvironment through processes such as proliferation, migration, and lumen formation. This process plays a crucial role in tumor metastasis and is an important mechanism for tumor lymphatic metastasis. Therefore, a deep understanding of the mechanism of lymphangiogenesis is crucial for finding new therapeutic targets and early diagnostic biomarkers. The purpose of this review is to explore the molecular mechanisms of lymphangiogenesis and analyze the interaction between tumor microenvironment and lymphatic endothelial cells, aiming to provide a new perspective for the research and clinical diagnosis and treatment of lymphangiogenesis.
关键词	恶性肿瘤；淋巴转移；淋巴管生成；肿瘤微环境
KeyWord	Malignant tumor ; Lymphatic metastasis; Lymphangiogenesis; Tumor microenvironment
基金项目
页码	35-40

参考文献
相关文献

[1] Zhang C, Dong HK, Gao JM, et al. Advances in the diagnosis and treatment of MET-variant digestive tract tumors. World J Gastrointest Oncol. 2024 Nov 15;16(11):4338-4353.
[2] Maoz A, Rodriguez NJ, Yurgelun MB, et al. Gastrointestinal Cancer Precursor Conditions and Their Detection. Hematol Oncol Clin North Am. 2024 Aug;38(4):783-811.
[3] .Diao X, Guo C, Li S. Progress in the Mechanism of Lymphangiogenesis and Lymphatic Metastasis of Non-small Cell Lung Cancer]. Zhongguo Fei Ai Za Zhi. 2021 Dec 20;24(12):874-880. Chinese.
[4] Hu Z, Zhao X, Wu Z, et al. Lymphatic vessel: origin, heterogeneity, biological functions, and therapeutic targets. Signal Transduct Target Ther. 2024 Jan 3;9(1):9. doi: 10.1038/s41392-023-01723-x. PMID: 38172098; PMCID: PMC10764842.
[5] 郭梦丽.壁虎粗多肽抑制肝癌淋巴管生成的作用及机制研究
[D].河南科技大学,2018.
[6] Song CY, Hsieh SL, Yang SY, et al. Visfatin Facilitates VEGF-D-Induced Lymphangiogenesis through Activating HIF-1α and Suppressing miR-2277-3p in Human Chondrosarcoma. Int J Mol Sci. 2024 May 9;25(10):5142.
[7] Kawamura K, Lee C, Yoshikawa T, et al. Prediction of cervical lymph node metastasis from immunostained specimens of tongue cancer using a multilayer perceptron neural network. Cancer Med. 2023 Mar;12(5):5312-5322.
[8] Chennakesavalu M, Somala SRR, Dommaraju SR, et al. Corneal6.Song CY, Hsieh SL, Yang SY, Lin CY, Wang SW, Tsai CH, Lo YS, Fong YC, Tang CH. Visfatin Facilitates VEGF-D-Induced Lymphangiogenesis through Activating HIF-1α and Suppressing miR-2277-3p in Human Chondrosarcoma. Int J Mol Sci. 2024 May 9;25(10):5142.
[9] Zhang X, Ma L, Xue M, et al. Advances in lymphatic metastasis of non-small cell lung cancer. Cell Commun Signal. 2024 Apr 2;22(1):201. doi: 10.1186/s12964-024-01574-1. PMID: 38566083; PMCID: PMC10986052.
[10] Lin S, Chai Y, Zheng X, et al. The role of HIF in angiogenesis, lymphangiogenesis, and tumor microenvironment in urological cancers. Mol Biol Rep. 2023 Dec 12;51(1):14.
[11] Ji H, Hu C, Yang X, et al. Lymph node metastasis in cancer progression: molecular mechanisms, clinical significance and therapeutic interventions. Signal Transduct Target Ther. 2023 Sep 27;8(1):367.
[12] Zhang Z, Zhao R, Wu X, et al. Research progress on the correlation between corneal neovascularization and lymphangiogenesis (Review). Mol Med Rep. 2025 Feb;31(2):47.
[13] Mariotti V, Fiorotto R, Cadamuro M, et al. New insights on the role of vascular endothelial growth factor in biliary pathophysiology. JHEP Rep. 2021 Feb 4;3(3):100251. doi: 10.1016/j.jhepr.2021.100251. PMID: 34151244; PMCID: PMC8189933.
[14] Cong B, Cao X, Jiang WG, Ye L. Molecular and Cellular Machinery of Lymphatic Metastasis in Breast Cancer. Onco Targets Ther. 2025 Feb 4;18:199-209.
[15] Dieterich LC, Tacconi C, Ducoli L, et al. Lymphatic vessels in cancer. Physiol Rev. 2022 Oct 1;102(4):1837-1879.
[16] Savetsky IL, Ghanta S, Gardenier JC, et al. Th2 cytokines inhibit lymphangiogenesis. PLoS One. 2015 Jun 3;10(6):e0126908. doi: 10.1371/journal.pone.0126908. PMID: 26039103; PMCID: PMC4454507.
[17] Singla B, Aithbathula RV, Pervaiz N, et al. CD47 Activation by Thrombospondin-1 in Lymphatic Endothelial Cells Suppresses Lymphangiogenesis and Promotes Atherosclerosis. Arterioscler Thromb Vasc Biol. 2023 Jul;43(7):1234-1250.
[18] Mondal DK, Xie C, Pascal GJ, et al. Decorin suppresses tumor lymphangiogenesis: A mechanism to curtail cancer progression. Proc Natl Acad Sci U S A. 2024 Apr 30;121(18):e2317760121. doi: 10.1073/pnas.2317760121. Epub 2024 Apr 23. PMID: 38652741; PMCID: PMC11067011.
[19] 赵红博,熊桂宏,李明秋.抑制肿瘤血管淋巴管生成的VEGFR分子机制及调控的研究进展
[J].中国医学创新,2023,20(15):184-188.
[20] 周玥莹,曲义坤.过表达趋化因子CXCL1在胃癌中的作用及研究进展
[J].中国医药导报,2024,21(05):49-52.
[21] Liu P, Ding P, Sun C, et al. Lymphangiogenesis in gastric cancer: function and mechanism. Eur J Med Res. 2023 Oct 7;28(1):405.
[22] Li Y, Gao X, Huang Y, et al. Tumor microenvironment promotes lymphatic metastasis of cervical cancer: its mechanisms and clinical implications. Front Oncol. 2023 May 10;13:1114042. doi: 10.3389/fonc.2023.1114042. PMID: 37234990; PMCID: PMC10206119.
[23] Li JJ, Mao JX, Zhong HX, et al. Multifaceted roles of lymphatic and blood endothelial cells in the tumor microenvironment of hepatocellular carcinoma: A comprehensive review. World J Hepatol. 2024 Apr 27;16(4):537-549.
[24] Pal S, Bhowmick S, Sharma A, et al. Lymphatic vasculature in ovarian cancer. Biochim Biophys Acta Rev Cancer. 2023 Sep;1878(5):188950. doi: 10.1016/j.bbcan.2023.188950. Epub 2023 Jul 5. PMID: 37419192; PMCID: PMC10754213.
[25] Lin S, Chai Y, Zheng X, et al. The role of HIF in angiogenesis, lymphangiogenesis, and tumor microenvironment in urological cancers. Mol Biol Rep. 2023 Dec 12;51(1):14.
[26] Kazakova A, Sudarskikh T, Kovalev O, et al. Interaction of tumor associated macrophages with stromal and immune components in solid tumors: Research progress (Review). Int J Oncol. 2023 Feb;62(2):32.
[27] Wang M, Zhao J, Zhang L, et al. Role of tumor microenvironment in tumorigenesis. J Cancer. 2017 Feb 25;8(5):761-773. doi: 10.7150/jca.17648. PMID: 28382138; PMCID: PMC5381164.
[28] Xu L, Wang X, Wang B, et al. The global landscape and research trend of lymphangiogenesis in breast cancer: a bibliometric analysis and visualization. Front Oncol. 2024 Mar 14;14:1337124.
[29] Menzel L, Höpken UE, Rehm A. Angiogenesis in Lymph Nodes Is a Critical Regulator of Immune Response and Lymphoma Growth. Front Immunol. 2020 Dec 3;11:591741.
[30] Chida K, Oshi M, An N, et al. Gastric cancer with enhanced myogenesis is associated with less cell proliferation, enriched epithelial-to-mesenchymal transition and angiogenesis, and poor clinical outcomes. Am J Cancer Res. 2024 Jan 15;14(1):355-367. doi: 10.62347/NCIM3072. PMID: 38323295; PMCID: PMC10839307.
[31] Park MS, Kim SE, Lee P, et al. Potential role of ANGPTL4 in cancer progression, metastasis, and metabolism: a brief review. BMB Rep. 2024 Aug;57(8):343-351.
[32] Lampejo AO, Fonseca Perez L, Girgis MM, et al. A Novel in vivo Rat Mesentery Model for Studying Tumor Spheroid-Induced Microvascular Remodeling. J Vasc Res. 2024 Dec 19:1-15.
[33] Schlereth SL, Refaian N, Iden S, et al. Impact of the prolymphangiogenic crosstalk in the tumor microenvironment on lymphatic cancer metastasis. Biomed Res Int. 2014;2014:639058.
[34] Ju W, Cai HH, Zheng W, et al. Cross talk between lymphangiogenesis and malignant melanoma cells: New opinions on tumour drainage and immunization (Review). Oncol Lett. 2024 Jan 5;27(2):81.

引用本文

李姣,郑盛*,杨涓. 恶性肿瘤淋巴管生的研究进展 [J]. 国际临床研究杂志. 2025; 9; (5). 35 - 40.

文献评论

相关学者

相关机构